Lakefront Biotherapeutics (GLPGF) Operating Expenses (2014 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Operating Expenses for 12 consecutive years, with -$29.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses rose 72.52% year-over-year to -$29.6 million in Q2 2026; TTM through Jun 2026 was -$277.5 million, a 32.47% increase from a year earlier, with the FY2025 full-year figure at -$519.0 million, down 42.94% from the prior year.
• Operating Expenses was -$29.6 million for Q2 2026 at Lakefront Biotherapeutics, up from -$36.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at -$8.7 million in Q4 2024 and troughed at -$274.9 billion in Q4 2022.
• A 5-year average of -$17.3 billion and a median of -$82.8 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 99.93% in 2023 and plunged 1345.7% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at -$274.9 billion in 2022, then soared by 99.93% to -$204.6 million in 2023, then jumped by 95.77% to -$8.7 million in 2024, then sank by 1345.7% to -$125.1 million in 2025, then soared by 76.31% to -$29.6 million in 2026.
• The last three Operating Expenses figures came in at -$29.6 million (Q2 2026), -$36.3 million (Q1 2026), and -$125.1 million (Q4 2025), per Business Quant data.